Trials / No Longer Available
No Longer AvailableNCT02449135
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma
Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for pancreatic cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
Detailed description
By enrolling patients with pancreatic cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | interventional therapy | Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）. |
Timeline
- First posted
- 2015-05-20
- Last updated
- 2021-09-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02449135. Inclusion in this directory is not an endorsement.